NASDAQ$PAHC

Phibro Animal Health Corporation · Q1 2023 earnings

Q1 2023 earnings · · Investor relations

Briefing

Phibro's financial performance reflects typical seasonality trends and was in line with internal expectations.

Phibro Animal Health Corporation reported an 8% increase in net sales, reaching $232.5 million for the first quarter ended September 30, 2022. However, net income decreased by 41% to $3.9 million, and adjusted EBITDA saw a slight decrease of 1% to $22.1 million. The company reiterated its full-year net sales guidance of $960 million to $1 billion and adjusted EBITDA guidance of $113 million to $118 million.

  • Net sales increased by 8% to $232.5 million, driven by growth in Animal Health and Mineral Nutrition segments.
  • Net income decreased by 41% to $3.9 million due to higher SG&A expenses and foreign currency losses.
  • Adjusted EBITDA decreased slightly by 1% to $22.1 million.
  • Company reiterates full-year net sales and Adjusted EBITDA guidance, but revised guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS and Adjusted effective tax rate.

Headline financials

Total Revenue

$233M

Previous: $215M+8.3%
EPS (adj)

$0.21

Previous: $0.25-16.0%
Adjusted EBITDA

$22.1M

No prior period
Free Cash Flow

$3.86M

Previous: $6.53M-41.0%
Net Income

$3.86M

Previous: $6.53M-41.0%
Operating Income

$13.7M

Previous: $14.6M-6.4%
Gross Profit

$68.6M

Previous: $64.7M+6.1%
Cash & Equivalents

$76.3M

Previous: $41.2M+85.3%
Total Assets

$948M

Previous: $836M+13.4%

Revenue & EPS history

Phibro · Revenue · Quarterly

$233M

Q1 2023+8.3%vs Q1 2022
Beat estimate in 7 of 14 quarters(50%)
ActualEstimate

Revenue by segment

Phibro · $387M total across 6 segments · Q1 2023

  • Animal Health
    $155M
  • MFAs and other
    $92.8M
  • Mineral Nutrition
    $59.6M
  • Nutritional specialties
    $39.1M
  • Vaccines
    $23M
  • Performance Products
    $18M

Forward guidance

The Company reiterated its guidance for Net sales and Adjusted EBITDA and revised its guidance for Net income, Diluted EPS, Adjusted net income, Adjusted diluted EPS and Adjusted effective tax rate.

Tailwinds

  • Net sales of $960 million - $1 billion (unchanged)
  • Adjusted EBITDA of $113 - $118 million (unchanged)

Headwinds

  • Net income of $39 - $43 million, from $45 - $49 million
  • Diluted EPS of $0.96 - $1.06, from $1.11 - $1.21
  • Adjusted net income of $49 - $53 million, from $52 - $56 million
  • Adjusted diluted EPS of $1.21 - $1.31, from $1.28 - $1.38
  • Adjusted effective tax rate of 33%, from 30%

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 20 quarterly earnings reports · overlaid with Q1 2023

Historical avgQ1 2023

-0.1%

Avg return

Earnings day

+1.0%

Avg return

5 days after

-1.4%

Avg return

30 days after

56%

29 / 52 earnings

Positive

+22.0%

Q2 2026

Best reaction

-31.5%

Q4 2019

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2026-26.1%-37.5%-44.6%
Q2 2026+22.0%+26.2%+16.9%
Q1 2026+4.7%+10.2%-4.8%
Q3 2025+14.7%+26.9%+24.2%
Q2 2025+9.9%+16.8%+5.7%
Q1 2025+2.8%+11.8%+1.6%
Q4 2024+1.9%-0.3%+4.8%
Q3 2024+5.5%+8.0%+2.3%
Q2 2024+5.9%+12.5%+19.1%
Q1 2024-18.9%-19.3%-8.4%
Q4 2023-5.8%-2.0%-13.8%
Q3 2023-8.4%-8.0%-12.0%
Q2 2023-0.9%-1.3%-4.7%
Q1 2023-5.5%-8.0%-14.2%
Q4 2022-4.8%-7.4%-24.4%
Q3 2022-4.0%-2.9%-0.5%
Q2 2022+5.7%+13.7%+6.0%
Q1 2022-0.8%-0.3%-10.1%
Q4 2021-5.0%-1.0%-10.2%
Q3 2021+8.1%+3.9%+14.7%
Q2 2021+7.3%+7.9%+7.5%
Q1 2021+4.5%+8.1%+10.0%
Q4 2020+0.9%+4.6%-13.0%
Q3 2020-4.6%-4.8%+15.7%
Q2 2020+16.9%+14.0%+12.5%
Q1 2020-8.1%-4.8%-0.0%
Q4 2019-31.5%-35.0%-32.5%
Q3 2019-19.7%-17.2%-17.0%
Q2 2019-6.4%-10.4%-11.8%
Q1 2019-8.7%-12.5%-22.1%
Q4 2018-3.0%-7.0%-15.3%
Q3 2018+4.2%+3.2%+9.7%
Q2 2018+6.8%+4.4%+16.0%
Q1 2018-4.9%-8.2%-12.9%
Q4 2017-5.1%-2.4%-0.9%
Q3 2017+6.0%+10.9%+18.4%
Q2 2017+7.0%+12.1%+0.2%
Q1 2017+11.3%+8.9%+3.4%
Q4 2016+15.4%+24.9%+28.9%
Q3 2016-10.3%
Q2 2016-18.2%
Q1 2016-3.4%
Q4 2015-5.3%
Q3 2015+7.9%
Q2 2015+6.5%
Q1 2014+5.5%
Q1 2015+7.4%
Q2 2014+0.3%
Q4 2014+12.6%
Q4 2013+1.0%
Q3 2013+1.0%
Q3 2014+1.0%
Q2 2013
Q1 2013

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro